What are your top takeaways from ACC 2024?

In the field of critical care cardiology, DanGer Shock stands out as a key trial presented at ACC 2024 and simultaneously published in NEJM (Møller et al., PMID 38587239). The “splash” of DanGer Shock comes as it is the first randomized controlled trial to demonstrate a mortality benefit from a temporary mechanical circulatory support device in patients with acute myocardial infarction and cardiogenic shock (AMI-CS).

At 180 days, assignment to treatment with a micro-axial flow pump (Impella) conf...

My “top 3” takeaways were:

1. EMPACT MI trial – Empagliflozin vs placebo in acute MI patients at risk for CHF (EF <=45%) did not reduce the primary endpoint of time to first hospitalization for heart failure or call cause death but did reduce the relative risk of heart failure hospitalizations.
2. AEGIS-II trial- Weekly infusions of human apolipoprotein A1 post-MI did not lower risk of MI stroke or CV death.
3. STEP-HFpEF DM trial – Semaglutide significantly reduced heart failure symptoms (using KCCQ) an...

Here are my top three picks from the conference, along with my thoughts on their impact:

1. AEGIS-II Trial: This trial investigated the cardiovascular outcomes following apolipoprotein A-I infusions in patients with acute myocardial infarction. While the initial results showed no significant reduction in death, heart attack, or stroke risks at 90 days, it opens a new avenue in exploring protein-based therapies for myocardial infarction patients. The long-term outcomes could still hold potential ben...